• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Abdelhamid Khirallah, R., Saleh, H., Abdel-Moneim, H. (2021). ORAL CONTRACEPTIVE PILLS VERSUS ESTRADIOL VALERATE PRETREATMENT IN GONADOTROPHIN-RELEASING HORMONE ANTAGONIST PROTOCOL. ALEXMED ePosters, 3(4), 82-83. doi: 10.21608/alexpo.2021.104777.1306
Rania Mamdouh Abdelhamid Khirallah; Hisham Ali Saleh; Hesham Adel Abdel-Moneim. "ORAL CONTRACEPTIVE PILLS VERSUS ESTRADIOL VALERATE PRETREATMENT IN GONADOTROPHIN-RELEASING HORMONE ANTAGONIST PROTOCOL". ALEXMED ePosters, 3, 4, 2021, 82-83. doi: 10.21608/alexpo.2021.104777.1306
Abdelhamid Khirallah, R., Saleh, H., Abdel-Moneim, H. (2021). 'ORAL CONTRACEPTIVE PILLS VERSUS ESTRADIOL VALERATE PRETREATMENT IN GONADOTROPHIN-RELEASING HORMONE ANTAGONIST PROTOCOL', ALEXMED ePosters, 3(4), pp. 82-83. doi: 10.21608/alexpo.2021.104777.1306
Abdelhamid Khirallah, R., Saleh, H., Abdel-Moneim, H. ORAL CONTRACEPTIVE PILLS VERSUS ESTRADIOL VALERATE PRETREATMENT IN GONADOTROPHIN-RELEASING HORMONE ANTAGONIST PROTOCOL. ALEXMED ePosters, 2021; 3(4): 82-83. doi: 10.21608/alexpo.2021.104777.1306

ORAL CONTRACEPTIVE PILLS VERSUS ESTRADIOL VALERATE PRETREATMENT IN GONADOTROPHIN-RELEASING HORMONE ANTAGONIST PROTOCOL

Article 251, Volume 3, Issue 4, December 2021, Page 82-83  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2021.104777.1306
View on SCiNiTO View on SCiNiTO
Authors
Rania Mamdouh Abdelhamid Khirallah email ; Hisham Ali Saleh; Hesham Adel Abdel-Moneim
Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University
Abstract
In ICSI cycle’s controlled ovarian hyperstimulation is an important parameter of the success rates.
Premature LH surge may complicate ovarian stimulation and decrease the pregnancy rate, suppression of endogenous LH can be achieved by GnRH antagonist protocols.
GnRH antagonists results in immediate down regulation of pituitary gland, thus allowing for shorter period of suppression, reduced duration of stimulation and associated with lower incidence of OHSS.
Advantages of pretreatment are more synchronous follicular development, higher number of oocytes, programming for cycle start and programming oocyte retrieval day.
Advantages of E2 versus OCPs are, duration of pretreatment is shorter, a good alternative for patients who have objections to or present contraindications for taking OCPs, E2 doesn’t affect the fertility potential during the cycle preceding ovarian stimulation.
Follicular phase estradiol scheduling does not seem to increasegonadotropin consumption or hamper clinical outcome.
AIM OF THE WORK:
The aim of the work was to compare pretreatment with OCPs with pretreatment with follicular estradiol valerate 8mg in antagonist protocol cycles for patients undergoing ICSI.
Keywords
ESTRADIOL VALERATE; ORAL CONTRACEPTIVE PILLS; GONADOTROPHIN-RELEASING HORMONE ANTAGONIST
Supplementary Files
download 0082-1306 Presentation12 (2).pdf
Statistics
Article View: 91
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.